Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

医学 紫杉醇 表阿霉素 内科学 肿瘤科 乳腺癌 环磷酰胺 多西紫杉醇 临床终点 化疗 新辅助治疗 泌尿科 胃肠病学 癌症 临床试验
作者
Oleg Gluz,Sherko Küemmel,Ulrike Nitz,Michael Braun,Kerstin Lüdtke-Heckenkamp,Raquel von Schumann,Maren Darsow,Helmut Forstbauer,Jochem Potenberg,Christoph Uleer,Eva‐Maria Grischke,Bahriye Aktas,Claudia Schumacher,Christine zu Eulenburg,Ronald Kates,Katarzyna Jóźwiak,Monika Graeser,Rachel Wuerstlein,R. Baehner,Matthias Christgen
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34 (6): 531-542 被引量:12
标识
DOI:10.1016/j.annonc.2023.04.002
摘要

•16-week neoadjuvant nab-paclitaxel induces higher pCR than sb-paclitaxel–epirubicin/cyclophosphamide in high-risk HR+/HER2− breast cancer.•First prospective phase III trial showed that higher RS is predictive for pCR.•Associations of higher RS and ET non-response with pCR are moderated by menopausal status (and/or ET agent used).•pCR mitigates the unfavorable impact of higher RS on dDFS.•Further trials should investigate therapy de-escalation in patients with RS >25, ET response, and lower clinical risk. BackgroundIn high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) early breast cancer (EBC), nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy versus solvent-based (sb)-paclitaxel in neoadjuvant trials; however, optimal patient and therapy selection remains a topic of ongoing research. Here, we investigate the potential of Oncotype DX® recurrence score (RS) and endocrine therapy (ET) response (low post-endocrine Ki67) for therapy selection.Patients and methodsWithin the WSG-ADAPT trial (NCT01779206), high-risk HR+/HER2− EBC patients were randomized to (neo)adjuvant 4× sb-paclitaxel 175 mg/m2 q2w or 8× nab-paclitaxel 125 mg/m2 q1w, followed by 4× epirubicin + cyclophosphamide (90 mg + 600 mg) q2w; inclusion criteria: (i) cN0-1, RS 12-25, and post-ET Ki67 >10%; (ii) cN0-1 with RS >25. Patients with cN2-3 or (G3, baseline Ki67 ≥40%, and tumor size >1 cm) were allowed to be included without RS and/or ET response testing. Associations of key factors with pathological complete response (pCR) (primary) and survival (secondary) endpoints were analyzed using statistical mediation and moderation models.ResultsEight hundred and sixty-four patients received neoadjuvant nab-paclitaxel (n = 437) or sb-paclitaxel (n = 427); nab-paclitaxel was superior for pCR (20.8% versus 12.9%, P = 0.002). pCR was higher for RS >25 versus RS ≤25 (16.0% versus 8.4%, P = 0.021) and for ET non-response versus ET response (15.1% versus 6.0%, P = 0.027); no factors were predictive for the relative efficacy of nab-paclitaxel versus sb-paclitaxel. Patients with pCR had longer distant disease-free survival [dDFS; hazard ratio 0.42, 95% confidence interval (CI) 0.20-0.91, P = 0.024]. Despite favorable prognostic association of RS >25 versus RS ≤25 with pCR (odds ratio 3.11, 95% CI 1.71-5.63, P ≤ 0.001), higher RS was unfavorably associated with dDFS (hazard ratio 1.03, 95% CI 1.01-1.05, P = 0.010).ConclusionsIn high-risk HR+/HER2− EBC, neoadjuvant nab-paclitaxel q1w appears superior to sb-paclitaxel q2w regarding pCR. Combining RS and ET response assessment appears to select patients with highest pCR rates. The disadvantage of higher RS for dDFS is reduced in patients with pCR. These are the first results from a large neoadjuvant randomized trial supporting the use of RS to help select patients for neoadjuvant chemotherapy in high-risk HR+/HER2− EBC. In high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) early breast cancer (EBC), nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy versus solvent-based (sb)-paclitaxel in neoadjuvant trials; however, optimal patient and therapy selection remains a topic of ongoing research. Here, we investigate the potential of Oncotype DX® recurrence score (RS) and endocrine therapy (ET) response (low post-endocrine Ki67) for therapy selection. Within the WSG-ADAPT trial (NCT01779206), high-risk HR+/HER2− EBC patients were randomized to (neo)adjuvant 4× sb-paclitaxel 175 mg/m2 q2w or 8× nab-paclitaxel 125 mg/m2 q1w, followed by 4× epirubicin + cyclophosphamide (90 mg + 600 mg) q2w; inclusion criteria: (i) cN0-1, RS 12-25, and post-ET Ki67 >10%; (ii) cN0-1 with RS >25. Patients with cN2-3 or (G3, baseline Ki67 ≥40%, and tumor size >1 cm) were allowed to be included without RS and/or ET response testing. Associations of key factors with pathological complete response (pCR) (primary) and survival (secondary) endpoints were analyzed using statistical mediation and moderation models. Eight hundred and sixty-four patients received neoadjuvant nab-paclitaxel (n = 437) or sb-paclitaxel (n = 427); nab-paclitaxel was superior for pCR (20.8% versus 12.9%, P = 0.002). pCR was higher for RS >25 versus RS ≤25 (16.0% versus 8.4%, P = 0.021) and for ET non-response versus ET response (15.1% versus 6.0%, P = 0.027); no factors were predictive for the relative efficacy of nab-paclitaxel versus sb-paclitaxel. Patients with pCR had longer distant disease-free survival [dDFS; hazard ratio 0.42, 95% confidence interval (CI) 0.20-0.91, P = 0.024]. Despite favorable prognostic association of RS >25 versus RS ≤25 with pCR (odds ratio 3.11, 95% CI 1.71-5.63, P ≤ 0.001), higher RS was unfavorably associated with dDFS (hazard ratio 1.03, 95% CI 1.01-1.05, P = 0.010). In high-risk HR+/HER2− EBC, neoadjuvant nab-paclitaxel q1w appears superior to sb-paclitaxel q2w regarding pCR. Combining RS and ET response assessment appears to select patients with highest pCR rates. The disadvantage of higher RS for dDFS is reduced in patients with pCR. These are the first results from a large neoadjuvant randomized trial supporting the use of RS to help select patients for neoadjuvant chemotherapy in high-risk HR+/HER2− EBC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
夏花苍葬发布了新的文献求助10
2秒前
MADKAI发布了新的文献求助10
3秒前
3秒前
3秒前
vicky完成签到 ,获得积分10
3秒前
朴素的擎宇完成签到,获得积分10
4秒前
4秒前
巫马百招完成签到,获得积分10
4秒前
倪婷晏发布了新的文献求助10
5秒前
上官若男的应助被学无止境采纳,获得10
5秒前
赘婿的应助被LWJ采纳,获得10
6秒前
H星科23456发布了新的文献求助10
7秒前
9秒前
粽子大王完成签到 ,获得积分10
9秒前
哎呀发布了新的文献求助10
9秒前
啊咻完成签到,获得积分10
10秒前
小肆发布了新的文献求助10
10秒前
11秒前
Akim的应助被爽歪歪采纳,获得10
11秒前
11秒前
风趣的雨灵完成签到,获得积分10
11秒前
12秒前
白三羽发布了新的文献求助10
13秒前
14秒前
15秒前
你好好想想完成签到 ,获得积分10
15秒前
学无止境完成签到,获得积分10
16秒前
Ava的应助被tjf采纳,获得10
16秒前
科研通AI6.2的应助被吴冠超采纳,获得10
16秒前
16秒前
16秒前
16秒前
popopanda完成签到,获得积分10
17秒前
17秒前
传奇3的应助被假正经先生采纳,获得10
18秒前
学无止境发布了新的文献求助10
19秒前
刘晓莹发布了新的文献求助10
19秒前
爆米花的应助被66采纳,获得10
19秒前
lameliu发布了新的文献求助10
19秒前
南笙发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163460
求助须知:如何正确求助?哪些是违规求助? 9557533
关于积分的说明 21740952
捐赠科研通 7754106
什么是DOI,文献DOI怎么找? 3428210
关于科研通互助平台的介绍 2552965
邀请新用户注册赠送积分活动 2472896